XRTX · XORTX Therapeutics Inc.

XORTX Therapeutics has finalized its strategic acquisition of the Vectus kidney anti-fibrotic asset, marking a significant expansion of its pipeline in progressive kidney disease. The transaction, valued at US$3.0 million, was executed through the issuance of common shares and pre-funded warrants, with the TSX Venture Exchange providing conditional approval for the listing of the shares. The acquired program centers on VB4-P5, a novel chemical entity at the pre-IND development stage that targets kidney fibrosis—a hallmark of chronic kidney disease progression affecting millions globally. According to CEO Dr. Allen Davidoff, this acquisition aligns directly with XORTX's strategic focus on developing innovative therapies for progressive kidney disease and introduces a new technological direction. The program comes with substantial intellectual property protection, including composition-of-matter and method-of-use claims across more than 30 global jurisdictions, positioning it for broad development and commercialization. Early preclinical data suggest VB4-P5 has the potential to inhibit and possibly reverse kidney fibrosis, addressing a critical unmet need as no currently approved therapies specifically target or reverse this condition. This acquisition broadens XORTX's therapeutic approach beyond its existing programs focused on purine metabolism and xanthine oxidase inhibition, potentially creating new treatment options for mid-late stage chronic kidney disease patients.